all

Further analysis from the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health (AIM-HIGH) trial was presented on November 15, 2011, at the American Heart Association (AHA) 2011 Scientific Sessions.

Abstract: With an occurrence of approximately 1 in 500 individuals worldwide, the heterozygous form of familial hypercholesterolemia is not uncommon. With statins being contraindicated in pregnancy (Category X), the management of pregnant women who carry this diagnosis has not been clearly defined. This case series describes five pregnant women seen at the Emory Center for Heart Disease Prevention between 2004 and 2010 who carried this diagnosis, their treatment, and subsequent outcomes.

On February 28, 2012, the Food and Drug Administration (FDA) approved crucial changes to the safety label for statins. The changes are based upon the FDA's further review of the data and are as follows: